title: Misuse of androgenic-anabolic steroids and human deltoid muscle fibers: differences between polydrug regimens and single drug administration.
abstract: The objective of this investigation was to study the effects of androgenic-anabolic steroid (AAS) misuse on deltoid muscle fiber characteristics in experienced, male strength-trained athletes. In a double-blind study, 15 volunteers were administered nandrolone decanoate (ND) for 8 weeks (200 mg/week, intramuscularly). In an additional study, 12 subjects self-administered various AASs at supratherapeutic dosages (AAS group), while 7 non-users served as controls. In all subjects, a percutaneous needle biopsy sample of the deltoid muscle was obtained at baseline and after 8 weeks. Muscle sections were pre-incubated at pH 4.4, stained with adenosine triphosphatase and analyzed morphometrically. In each biopsy sample, at least 150 fibers were classified for "gray level" and "lesser fiber diameter" to determine the mean fiber size, the sizes of type I and type II fibers, and the fiber type distribution. ND administration did not seem to affect any of those parameters. In the AAS group, mean muscle fiber size (+ 12.6%), and the size of type I (+ 10.8%) and type II (+ 14.6%) muscle fibers increased. The fiber type distribution remained unaltered. We conclude that polydrug regimens of AAS misuse at supratherapeutic dosages increased the size of deltoid muscle fibers (especially type II fibers) in experienced strength-trained athletes, while ND at a therapeutic intramuscular dose of 200 mg did not exert any effect.
authors: Netherlands Centre for Doping Affairs, Capelle aan den IJssel, The Netherlands. fred.hartgens@bw.unimaas.nl
authors: F
authors: F
authors: Hartgens
authors: H
authors: H
authors: van Straaten
authors: S
authors: S
authors: Fideldij
authors: G
authors: G
authors: Rietjens
authors: H A
authors: HA
authors: Keizer
authors: H
authors: H
authors: Kuipers
mesh_terms: D000328:Adult; D045930:Anabolic Agents / Q000008:administration & dosage*; D001706:Biopsy; D004300:Doping in Sports; D004311:Double-Blind Method; D015444:Exercise / Q000502:physiology; D006801:Humans; D006984:Hypertrophy; D008297:Male; D018656:Muscle Fibers, Fast-Twitch / Q000166:cytology / Q000187:drug effects; D018657:Muscle Fibers, Slow-Twitch / Q000166:cytology / Q000187:drug effects; D018482:Muscle, Skeletal / Q000166:cytology / Q000187:drug effects* / Q000502:physiology; D009277:Nandrolone / Q000008:administration & dosage* / Q000031:analogs & derivatives*; D000077603:Nandrolone Decanoate; D011446:Prospective Studies
chemical_list: D045930:Anabolic Agents; D009277:Nandrolone; D000077603:Nandrolone Decanoate